SUNPG 1622

Drug Profile

SUNPG 1622

Alternative Names: SUNPG 1622 I; SUNPG1622

Latest Information Update: 07 Dec 2016

Price : $50

At a glance

  • Originator Sun Pharmaceutical Industries
  • Class Antirheumatics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase Unknown Ankylosing spondylitis

Most Recent Events

  • 30 Nov 2016 Investigation in Ankylosing spondylitis in USA (unspecified route) before November 2016
  • 30 Nov 2016 Sun Pharma Global FZE plans a phase IIa trial for Ankylosing spondylitis (Adjunctive treatment) in USA (NCT02980705)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top